Your browser doesn't support javascript.
loading
Host Cell Targets for Unconventional Antivirals against RNA Viruses.
Roa-Linares, Vicky C; Escudero-Flórez, Manuela; Vicente-Manzanares, Miguel; Gallego-Gómez, Juan C.
Afiliación
  • Roa-Linares VC; Molecular and Translation Medicine Group, University of Antioquia, Medellin 050010, Colombia.
  • Escudero-Flórez M; Molecular and Translation Medicine Group, University of Antioquia, Medellin 050010, Colombia.
  • Vicente-Manzanares M; Molecular Mechanisms Program, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer, Consejo Superior de Investigaciones Científicas (CSIC), University of Salamanca, 37007 Salamanca, Spain.
  • Gallego-Gómez JC; Molecular and Translation Medicine Group, University of Antioquia, Medellin 050010, Colombia.
Viruses ; 15(3)2023 03 17.
Article en En | MEDLINE | ID: mdl-36992484
The recent COVID-19 crisis has highlighted the importance of RNA-based viruses. The most prominent members of this group are SARS-CoV-2 (coronavirus), HIV (human immunodeficiency virus), EBOV (Ebola virus), DENV (dengue virus), HCV (hepatitis C virus), ZIKV (Zika virus), CHIKV (chikungunya virus), and influenza A virus. With the exception of retroviruses which produce reverse transcriptase, the majority of RNA viruses encode RNA-dependent RNA polymerases which do not include molecular proofreading tools, underlying the high mutation capacity of these viruses as they multiply in the host cells. Together with their ability to manipulate the immune system of the host in different ways, their high mutation frequency poses a challenge to develop effective and durable vaccination and/or treatments. Consequently, the use of antiviral targeting agents, while an important part of the therapeutic strategy against infection, may lead to the selection of drug-resistant variants. The crucial role of the host cell replicative and processing machinery is essential for the replicative cycle of the viruses and has driven attention to the potential use of drugs directed to the host machinery as therapeutic alternatives to treat viral infections. In this review, we discuss small molecules with antiviral effects that target cellular factors in different steps of the infectious cycle of many RNA viruses. We emphasize the repurposing of FDA-approved drugs with broad-spectrum antiviral activity. Finally, we postulate that the ferruginol analog (18-(phthalimide-2-yl) ferruginol) is a potential host-targeted antiviral.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus ARN / Virus / Virus Zika / Infección por el Virus Zika / COVID-19 Límite: Humans Idioma: En Revista: Viruses Año: 2023 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Suiza
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Virus ARN / Virus / Virus Zika / Infección por el Virus Zika / COVID-19 Límite: Humans Idioma: En Revista: Viruses Año: 2023 Tipo del documento: Article País de afiliación: Colombia Pais de publicación: Suiza